The successful collaborative project between Magnus Essand and Di Yu on one hand and the Drug Development and Discovery Platform (DDD) at SciLifeLab on the other reached the Exit Milestone after two and a half years. The project led to the development of a chimeric antigen receptor (CAR) targeting IL13R2a (ELC-401).
https://uu.se/en/news-media/news/article/?id=14932&typ=artikel&lang=en
The DDD Platform is a National Resource that helps researcher take academic findings into commercial product development.